Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.

@article{Hollak2010ForceMT,
  title={Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.},
  author={Carla E. M. Hollak and Stephan vom Dahl and Johannes M. F. G. Aerts and Nadia Belmatoug and Bruno Bembi and Yossi Cohen and Tanya Collin-Histed and Patrick Deegan and Laura van Dussen and Pilar Giraldo and Eugen Mengel and Helen M Michelakakis and Jeremy Manuel and Martin Hřeb{\'i}{\vc}ek and Rosella Parini and Joerg Reinke and M Di Rocco and Miguel Pocovi and Maria Clara Sa Miranda and Anna Tylki-Szymańska and Ari Zimran and Timothy Martin Cox},
  journal={Blood cells, molecules & diseases},
  year={2010},
  volume={44 1},
  pages={41-7}
}
Gaucher disease is the first lysosomal disorder for which clinically effective enzyme replacement therapy has been introduced. Lifelong treatment with imiglucerase, the recombinant glucocerebrosidase manufactured by the Genzyme Corporation (MA, USA), is administered intravenously - usually at biweekly intervals. An acute shortage of imiglucerase (to 20% of prior global supply) has occurred as a result of viral contamination of the production facility; production was halted, and a full supply of… CONTINUE READING